Preclinical and Toxicology Assessment of ALW-II-41-27, an Inhibitor of the Eph Receptor A2 (EphA2)

• Päätekijät: Theodore J. Kottom (Tekijä), Kimberly E. Stelzig (Tekijä), Madeline R. Pellegrino (Tekijä), Marc Bindzus (Tekijä), Eunhee S. Yi (Tekijä), Andrew H. Limper (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Background and Objective The EphA2 receptor inhibitor ALW-II-41-27 has proven to be an effective in vitro antagonist of Pneumocystis β-glucan-induced proinflammatory signaling. This suggests its potential as a candidate for initial anti-inflammatory drug testing in the rodent model of Pneum...